bioRxivMicrobiology
Antagonism of STAT3 signalling by Ebola virus
A. R. Harrison, M. Dearnley, S. Todd, D. Green, G. A. Marsh, G. W. Moseley
Abstract
Many viruses target signal transducers and activators of transcription (STAT) 1 and 2 to antagonise antiviral interferon (IFN) signalling, but targeting of signalling by other STATs/cytokines, including STAT3/interleukin (IL-) 6 that regulate processes important to Ebola virus (EBOV) haemorrhagic fever, is poorly defined. We report that EBOV potently inhibits STAT3 responses to IL-6 family cytokines, and that this is mediated by the IFN-antagonist VP24. Mechanistic analysis indicates that VP24 effects a unique strategy combining distinct karyopherin-dependent and karyopherin-independent mechanisms to antagonise STAT3-STAT1 heterodimers and STAT3 homodimers, respectively. This appears to reflect distinct mechanisms of nuclear trafficking of the STAT3 complexes, revealed for the first time by our analysis of VP24 function. These findings are consistent with major roles for global inhibition of STAT3 signalling in EBOV infection, and provide new insights into the molecular mechanisms of STAT3 nuclear trafficking, significant to pathogen-host interactions, cell physiology and pathologies such as cancer. Author summaryEbola virus (EBOV) continues to pose a significant risk to human health globally, causing ongoing disease outbreaks with case-fatality rates between 40 and 60%. Suppression of immune responses is a critical component of EBOV haemorrhagic fever, but understanding of EBOV impact on signalling by cytokines other than interferon is limited. We find that infectious EBOV inhibits interleukin-6 cytokine signalling via antagonism of STAT3. The antagonistic strategy uniquely combines two distinct mechanisms, which appear to reflect differing nuclear trafficking mechanisms of critical STAT3 complexes. This provides fundamental insights into the mechanisms of pathogenesis of a lethal virus, and biology of STAT3, a critical player in immunity, development, growth and cancer.
- research focus: host-pathogen & immune response
- research focus: cell signaling & trafficking
- research focus: chromatin & epigenetic regulation
- research focus: cancer & tumor microenvironment
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Ebola Virus Sequesters IRF3 in Viral Inclusion Bodies to Evade Host Antiviral Immunity
- The Ebola virus interferon antagonist VP24 undergoes active nucleocytoplasmic trafficking
A. R. Harrison, G. W. Moseley·bioRxiv·Aug 10, 2020
- Ebola virus exploits host lncRNA LINC01740 to enhance ATF3 and suppress antiviral immune responses
Olena Shtanko, Tanuj Gunturu, … Smita Kulkarni·bioRxiv·Jul 9, 2026
- Mutation of Ebola virus VP35 Ser129 uncouples interferon antagonist and replication functions
M. J. Morwitzer, A. Corona, … S. P. Reid·bioRxiv·Aug 7, 2019
- Ebola virus VP35 NNLNS motif modulates viral RNA synthesis and MIB2-mediated signaling
Grace Uwase, Priya Luthra, … Gaya K. Amarasinghe·Proceedings of the National Academy of SciencesPeer-reviewed·Sep 22, 2025
- CD81 is an Ebola virus inhibiting factor that is antagonized by GP and VP40
Dan Hu, Elena Hagelauer, … Michael Schindler·bioRxiv·Feb 4, 2026